Stocks · News reference
Maxim Group Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $5
Maxim Group analyst Anthony Vendetti maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $13 to $5.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NeuroOne Medical Technologies shares are trading higher after the company announced it has completed three separate large-animal procedures using its next-generation StereoCED platform.
NeuroOne Completes Three Large-Animal StereoCED Procedures, Including Combined Drug Delivery And Brain Recording; Builds Momentum Toward Planned Launch Of The StereoCED Platform For Human Investigational Clinical Studies Later This Quarter
Successful Large-Animal Procedures Build Momentum Toward Planned Launch of the StereoCED™ Platform for Human Investigational Clinical Studies Later This Quarter Related StereoCED™ Revenue Expected to be Recognized in
8-K filing — NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
Filed: 2026-08-27 AccNo: 0001213900-26-094174 Size: 228 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits